Latakia

Primary frontal hyperhidrosis is a chronic condition characterized by excessive sweating in the forehead area, which can greatly affect a persons quality of life due to its visibility and impact on daily activities. This research aims to assess the safety and effectiveness of intradermal injections of Botulinum Toxin Type A for treating this condition. Clinical outcomes will be evaluated using the Hyperhidrosis Disease Severity Scale HDSS, Minors iodine-starch test, and patient satisfaction scores, with follow-up one month after treatment to monitor results and side effects. Participants will receive injections of Botulinum Toxin Type A directly into the affected frontal area. The treatment area is identified using Minors iodine-starch test and divided into a grid for precise injection placement. Each injection delivers 2 units of the toxin, with a total dose ranging from 40 to 80 units depending on the size of the affected region. The injections are given using a fine needle, and the treatment is performed during a single visit. During the study, participants will undergo baseline assessments including the HDSS score and Minors test to map sweating areas. One month after treatment, these assessments will be repeated to measure changes in sweating severity and area. Patient satisfaction will also be recorded using a questionnaire. Safety monitoring will include tracking any adverse effects experienced during the follow-up period. The study is conducted on adults aged 18 to 40 years and aims to provide detailed data on treatment effects and safety over this four-week period.

This clinical study is investigating the use of patient-specific 3D-printed titanium implants for reconstructing facial defects and improving facial appearance. It includes adults with congenital, traumatic, or post-surgical facial deformities that require reconstructive surgery. The aim is to evaluate the safety, effectiveness, and functional and aesthetic outcomes of these customized implants compared to traditional methods. Participants will undergo detailed preoperative assessments including clinical exams and high-resolution CT scans. Customized implants are designed using computer-aided design CAD and produced with selective laser melting 3D printing technology from medical-grade titanium. Surgical placement follows standard maxillofacial protocols with fixation to bone as needed. Follow-up includes clinical and radiological exams for up to 12 months after surgery. Throughout the study, participants will have assessments to monitor implant fit, stability, complications, facial symmetry, and patient satisfaction. Outcome measures include postoperative complication rates over six months, implant geometric accuracy immediately after printing, and aesthetic improvement scores at three months. Patient satisfaction and total surgery time are also recorded to evaluate the overall success and safety of this reconstructive approach.

Researchers are evaluating the effectiveness and pain response of two local anesthesia methods in children undergoing dental treatment using an electronic syringe. The study focuses on ligament anesthesia and the inferior alveolar nerve block IANB technique, each applied to different teeth during separate visits. This trial explores the benefits of computerized syringes that offer precise control of anesthetic flow and include features designed to reduce fear and anxiety in pediatric patients. The study compares two anesthesia methods delivered with an electronic syringe one using the inferior alveolar nerve block technique and the other using intraligamentary anesthesia around the tooth ligament. Both techniques involve controlled injection speed and pressure to minimize discomfort. Each child undergoes pulpectomy for two different teeth, receiving a different anesthesia technique at each visit to allow direct comparison. Participants will be assessed for pain during anesthesia administration, rubber dam placement, and pulp chamber opening using age-appropriate pain scales. Researchers will also evaluate childrens and parents satisfaction with the electronic syringe. The main outcomes include the success rates of the anesthesia techniques during the dental procedures. The study runs from May 2025 to April 2026 and includes children aged 6 to 10 years.

Researchers are evaluating the effectiveness of using resin infiltration with and without sodium hypochlorite to manage opacities caused by Molar Incisor Hypomineralisation MIH on permanent incisors. The study aims to compare how well the treatments improve the appearance of the affected teeth and to assess parents satisfaction with each treatment method. Participants teeth will be randomly assigned to either a test group or a control group. The test group will receive sodium hypochlorite 5.25% applied with a cotton wad before treatment and after the first two etching cycles, followed by resin infiltration using ICON products. The control group will follow the same procedure but without sodium hypochlorite. The treatments involve cycles of etching and application of resin infiltrant according to the manufacturers instructions. During the study, researchers will measure the masking effectiveness of the treatments on day 1 and again 7 to 10 days later using color analysis software to compare the opacity with adjacent enamel. They will also evaluate the percentage of the opacity infiltrated. Additionally, parents satisfaction with the treatment results will be assessed using a Likert scale at the same time points. The study is randomized and unblinded, with a total participation period spanning these initial assessments.

Researchers are investigating the effect of Ursodeoxycholic Acid UDCA combined with triple phototherapy in treating indirect hyperbilirubinemia in newborns born at or after 34 weeks of gestation. This open-label, randomized controlled trial aims to see if adding UDCA can help lower bilirubin levels faster or reduce the time needed for phototherapy compared to phototherapy alone. The study is conducted at Lattakia University Hospital and includes stratification based on jaundice cause, such as hemolytic, non-hemolytic, or G6PD deficiency. Newborns meeting the criteria will be randomly assigned to one of two groups one receiving continuous triple phototherapy alone, and the other receiving the same phototherapy plus oral UDCA at 10 mg per kg per day split into two doses. The UDCA is given with feeding until bilirubin levels fall below the treatment threshold. Phototherapy follows American Academy of Pediatrics guidelines, and participants are monitored closely during treatment. Parents can expect their newborns to have bilirubin levels checked every 12 hours until discharge. The main measures are the time and rate at which bilirubin decreases below phototherapy thresholds within seven days. Secondary outcomes include hospital stay length, bilirubin reduction differences between late preterm and term infants, need for retreatment, and monitoring for any side effects in the UDCA group. The study continues until bilirubin normalizes or treatment ends, with follow-up up to 10 days after discontinuation.